Peer-reviewedCC BY-NC-NDInternal Medicine
Combined Hepatocellular-cholangiocarcinoma Patient Treated with Durvalumab Plus Gemcitabine and Cisplatin
Abstract
A 55-year-old man with lower abdominal pain and diarrhea was referred to our hospital. Computed tomography (CT) revealed a hypovascular liver tumor, lymph node/bone metastases, and peritoneal dissemination. Based on a histological analysis of lymph node metastasis, he was diagnosed with combined hepatocellular-cholangiocarcinoma (cHCC-CCA) and received durvalumab plus gemcitabine and cisplatin (Dur/GC). After treatment, the patient developed grade 2 diarrhea and grade 3 thrombocytopenia. CT after one course of Dur/GC demonstrated tumor shrinkage and expanded peritoneal dissemination, suggesting the need for further studies on the efficacy and safety of this therapy for unresectable cHCC-CCA.
Related
- Clinical Management and Molecular Landscape of Combined Hepatocellular–Cholangiocarcinoma: A Comprehensive Review
- Dynamic contrast-enhanced MRI deep learning model combined with clinical model for noninvasive differentiation of hepatocellular carcinoma from mass-forming intrahepatic cholangiocarcinoma
- Cadonilimab plus gemcitabine and cisplatin as first-line treatment for unresectable locally advanced or metastatic biliary tract malignancies: the phase II bicureX clinical trial
- Pembrolizumab plus gemcitabine and cisplatin for advanced biliary tract cancer: longer-term follow-up from the randomised, double-blind, placebo-controlled, phase 3 KEYNOTE-966 trial
- Long-Term Outcomes of a Multidisciplinary Treatment Strategy Using Neoadjuvant Gemcitabine Plus S-1 Based on Anatomical Resectability Classification and Lymph Node Status in Patients with Perihilar Cholangiocarcinoma
BibTeX
@article{kobayashi2026combined,
title = {{Combined Hepatocellular-cholangiocarcinoma Patient Treated with Durvalumab Plus Gemcitabine and Cisplatin}},
author = {Daisuke Kobayashi and Manabu Hayashi and Yosuke Takahata and Masashi Fujita and Naoto Abe and Tatsuro Sugaya and Kazuki Akaike and Kentaro Sato and Hiroshi Shimizu and Hiroyuki Asama and Kazumichi Abe and Yasuyuki Kobayashi and Yuko Hashimoto and Takuto Hikichi and Hiromasa Ohira},
journal = {Internal Medicine},
year = {2026},
month = oct,
doi = {10.2169/internalmedicine.6512-25},
url = {https://www.jstage.jst.go.jp/article/internalmedicine/65/20/65_6512-25/_article},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Combined Hepatocellular-cholangiocarcinoma Patient Treated with Durvalumab Plus Gemcitabine and Cisplatin
AU - Daisuke Kobayashi
AU - Manabu Hayashi
AU - Yosuke Takahata
AU - Masashi Fujita
AU - Naoto Abe
AU - Tatsuro Sugaya
AU - Kazuki Akaike
AU - Kentaro Sato
AU - Hiroshi Shimizu
AU - Hiroyuki Asama
AU - Kazumichi Abe
AU - Yasuyuki Kobayashi
AU - Yuko Hashimoto
AU - Takuto Hikichi
AU - Hiromasa Ohira
PY - 2026
DA - 2026/10/15
JO - Internal Medicine
DO - 10.2169/internalmedicine.6512-25
UR - https://www.jstage.jst.go.jp/article/internalmedicine/65/20/65_6512-25/_article
AB - A 55-year-old man with lower abdominal pain and diarrhea was referred to our hospital. Computed tomography (CT) revealed a hypovascular liver tumor, lymph node/bone metastases, and peritoneal dissemination. Based on a histological analysis of lymph node metastasis, he was diagnosed with combined hepatocellular-cholangiocarcinoma (cHCC-CCA) and received durvalumab plus gemcitabine and cisplatin (Dur/GC). After treatment, the patient developed grade 2 diarrhea and grade 3 thrombocytopenia. CT after one course of Dur/GC demonstrated tumor shrinkage and expanded peritoneal dissemination, suggesting the need for further studies on the efficacy and safety of this therapy for unresectable cHCC-CCA.
SN - 1349-7235
SN - 0918-2918
ER -